Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT05774080
Active, not recruiting Observational

An Observational Study of Patients With Chronic Gastrointestinal Disease

NCT05774080 · tracked via the Priya Life Science USA tracker
Sponsor
Target PharmaSolutions, Inc
Phase
Observational
Started
2023-08-01
Last updated
2026-01-29

Condition(s) studied

Gastrointestinal Diseases

Investigational drug(s) / intervention(s)

Observational

Observational: Observational

Study summary

TARGET-GASTRO is an observational research study to conduct a comprehensive review of outcomes for patients with the chronic gastrointestinal (GI) diseases: eosinophilic gastrointestinal disease (EGID), ulcerative colitis (UC) or Crohn's disease (CD).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Disease Cohort Inclusion Criteria: * Adult\* patients at the time of enrollment with a diagnosis or major symptom of EGIDs, UC, or CD by ICD-10 code in the EHR interface Exclusion Criteria: * Death * Manual removal (sponsor or site request) * No EHR interface encounter \> 3 years. Engaged Cohort Inclusion Criteria: * Adult\* patients diagnosed and managed for these conditions invited to participate * Ability to provide written informed consent Exclusion Criteria: * Patient expressed desire to withdraw consent to complete PROs * Failure to complete PROs within 24 weeks of initial invitation * Greater than 24 months lapse of survey completion after baseline surveys completed * Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

Primary outcome measure(s)

  • To characterize the natural history of disease in patients with GI disease from various etiologies — 20 Years
  • To assess safety and effectiveness of treatments — 20 Years

Trial sites (1)

FacilityCityRegionStatus
Atrium Health/Wake Forest University School of Medicine Winston-Salem North Carolina

More Target PharmaSolutions, Inc. trials in the USA

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease Active, not recruiting
An Observational Study of Patients With Dermatologic Disease Starting soon
An Observational Study of Patients With Chronic Liver Disease Enrolling by invitation
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC Active, not recruiting

Other trials for the same condition

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Active, not recruiting
Correlation of Toxins With Gastrointestinal (GI) and Overall Health Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05774080 on ClinicalTrials.gov ↗ ← All trials in the USA